clinical trial · NCT04759664
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
EGFRI Induced Acneiform LesionsLUT014 Gel (Dose 1)LUT014 Gel (Dose 2)Placebo
brief summary
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions
started
Apr 12, 2021
primary completion
Mar 1, 2024
completion
May 1, 2024
last updated
Oct 6, 2023
official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients With EGFR Inhibitor Induced Acneiform Lesions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol